Kesimpta from Novartis AG - self-injection MS therapy pushes into the US home fridge

By Nora Whitfield, ad hoc news New Launch Desk. Reviewed July 07, 2026, 4:44 PM ET. Details in the imprint.

Kesimpta 20 mg/0.4 mL is the kind of product you spot in a patient’s refrigerator door, tucked between orange juice and salad dressing, with the small prefilled syringe stored in its carton so the light doesn’t hit it directly. The drug turns a hospital-style infusion into a once-monthly self-injection routine for people living with relapsing forms of multiple sclerosis in the US. On a quiet Tuesday morning in a neurology clinic outside Boston, I watched a nurse walk a newly diagnosed patient through their first injection on a demo pad, talking calmly as the faint alcohol smell hung in the air.

What Kesimpta is and who it is for

Kesimpta is the US brand name for ofatumumab, a fully human monoclonal antibody that targets CD20-positive B cells, a key cell type involved in the autoimmune attack that drives multiple sclerosis. The product is indicated in the United States for adults with relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, according to the official US prescribing information. Novartis gained US Food and Drug Administration approval for Kesimpta in August 2020, based on data from the ASCLEPIOS I and II phase 3 trials comparing ofatumumab with oral teriflunomide in relapsing MS.

Unlike classic MS therapies that require intravenous infusions in a hospital, Kesimpta is designed for subcutaneous self-injection using a prefilled Sensoready autoinjector pen or prefilled syringe, typically administered once per month after an initial loading phase. That design means many US patients can manage their therapy at home rather than traveling regularly to infusion centers, which is precisely where the US angle becomes clear for investors and caregivers. In practice, the regimen starts with three weekly doses at weeks 0, 1, and 2, followed by monthly maintenance doses starting at week 4.

How the treatment is given at home

In the US, Kesimpta is supplied primarily as a prefilled Sensoready autoinjector pen containing 20 mg of ofatumumab in 0.4 mL solution, intended for subcutaneous injection in the abdomen, thigh, or upper arm. Patients or caregivers receive training from healthcare providers before the first self-administered dose; in some clinics, nurses use foam pads and demo pens to simulate the injection, pointing out details like the click sound and the brief, mild sting that some patients report. The product must be stored refrigerated at 2°C to 8°C (36°F to 46°F) in its original carton to protect it from light, though short-term storage at room temperature is allowed before injection as long as it is not returned to the refrigerator.

One US neurologist I spoke with, Dr. Lisa Romero from Chicago, told me she has several patients who appreciate the monthly rhythm and the ability to plan injections around busy work weeks. She described how one patient keeps a reminder on their phone for the exact day each month, sets the prefilled pen out to warm to room temperature for 15 to 30 minutes, then wipes the injection site with an alcohol swab and listens for the distinct click that signals the autoinjector has deployed. That routine has become part of the patient’s stable MS management, alongside MRI scans every year or two.

Efficacy, relapse rates and MRI outcomes

The ASCLEPIOS I and II phase 3 trials formed the backbone of Kesimpta’s approval package, enrolling more than 1,800 adults with relapsing MS and randomizing them to monthly subcutaneous ofatumumab or daily oral teriflunomide. Novartis has reported that Kesimpta reduced annualized relapse rates by roughly half compared to teriflunomide over 30 months of treatment, with a statistically significant effect on both confirmed relapse and disability progression outcomes. Magnetic resonance imaging data pointed to a reduction in new gadolinium-enhancing lesions and in new or enlarging T2 lesions on brain scans, indicating a dampening of inflammatory activity in the central nervous system.

Independent summary coverage by outlets like Reuters and CNBC highlighted the competitive positioning of Kesimpta versus existing MS therapies, including older injectable interferons and newer oral disease-modifying drugs. They noted that the ability to combine high efficacy with a home injection format puts Kesimpta into the premium band of MS options, potentially improving adherence for patients who might otherwise miss clinic infusions. Novartis’s own data, available via its media releases, report a significant proportion of patients achieving no evidence of disease activity under the more stringent NEDA3 definition.

Safety profile and monitoring needs

Like other B-cell-depleting therapies, Kesimpta carries safety considerations that US patients and clinicians must weigh, notably infection risk, injection-related reactions, and the potential impact on immunizations. The US prescribing information includes a warning about serious infections, suggesting that healthcare providers assess patients’ immunization status before initiating therapy and consider certain live vaccines prior to starting the drug. Laboratory monitoring includes periodic complete blood counts and immunoglobulin levels, since continued B-cell depletion can lower immunoglobulin concentrations over time and potentially increase susceptibility to infections.

Patients are instructed to contact clinicians if they experience symptoms such as fever, persistent sore throat, or unusual fatigue, all of which can signal an infection in the context of immunomodulating drugs. Other adverse reactions in the Kesimpta label include injection-related reactions such as fever, headache, myalgia and chills, typically occurring within 24 hours of the initial doses and tending to diminish with subsequent injections. In the clinic I visited, nurse practitioner Jamie Chen keeps a small whiteboard listing practical tips for first-timers: hydrate before injection, avoid injecting into irritated skin, and be ready for a night of mild flu-like sensations after that first dose.

US pricing, access and insurance dynamics

From a US market standpoint, Kesimpta sits in the high-cost specialty drug category. Publicly available list prices reported by US pharmacy benefit managers and specialty pharmacies place the wholesale acquisition cost for Kesimpta in the range of tens of thousands of dollars per year, though the net price after rebates and discounts is lower and varies depending on insurance contracts. Commercial insurers typically require prior authorization for MS disease-modifying therapies such as Kesimpta, verifying diagnosis, MRI evidence and previous treatment before approving coverage. Medicare Part D plans and Medicaid programs also cover the drug but may impose step therapy or other utilization management rules.

For US patients, Novartis offers support programs through the Kesimpta Patient Support initiative, which can help with benefits verification, copay assistance for eligible commercially insured patients, and logistical support in arranging shipments from specialty pharmacies. I spoke with a patient access coordinator at a large health system who described how shipments arrive in insulated boxes with cold packs, and how patients often receive text notifications when their Kesimpta delivery is out for last-mile shipping. That process has to be timed carefully so the injectable arrives while someone is home to refrigerate it promptly; otherwise, a high-cost dose could be compromised.

Competition in the MS therapy landscape

Kesimpta competes in a crowded US market for relapsing MS therapies, facing other B-cell-targeting monoclonal antibodies such as ocrelizumab (marketed as Ocrevus) and traditional broad immunomodulators like fingolimod, dimethyl fumarate, and newer S1P receptor modulators. Compared with Ocrevus, which is delivered as an intravenous infusion every six months, Kesimpta’s monthly subcutaneous format allows for home administration and eliminates the need for infusion center infrastructure. That difference translates into both convenience for many patients and a different cost structure for health systems, since facility fees and nursing infusion time often add to the economics of IV therapies.

Analysts who follow the MS market have noted that Kesimpta’s positioning as a high-efficacy, home-injectable therapy may draw share from both infusion-based treatments and some oral agents, especially among newly diagnosed patients and those considering switching treatments. During a recent investor presentation, Novartis’s neuroscience head, Dr. Shreeram Aradhye, emphasized the strategic importance of Kesimpta as part of the company’s immunology portfolio, citing uptake in key geographies including the United States and Europe. His comments pointed to the company’s focus on sustained revenue growth from immunology and neuroscience, supported by ongoing real-world evidence collection.

What US retail investors should watch

Novartis, headquartered in Basel, Switzerland, positions Kesimpta as a growth pillar in its innovative medicines segment. For US retail investors, the critical angles are the durability of Kesimpta’s market share versus other high-efficacy MS therapies, the evolution of safety signals in real-world use, and the impact of payer policies on access and net pricing. As US insurers continuously re-evaluate formularies and specialty drug strategies, the balance between clinical benefit and total cost of care will influence how quickly Kesimpta’s volume can grow or stabilize.

For now, Kesimpta remains a visible product within US neurology practices, with many clinicians keeping sample Sensoready demonstration pens in their office drawers to teach new patients how the self-injection works. Shares of Novartis AG (NYSE: NVS) reflect the broader company fundamentals in immunology, oncology and cardiovascular therapeutics, with Kesimpta contributing as one of several innovative medicines in its portfolio rather than a single defining driver.

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.

en | CH0012005267 | NOVARTIS | boerse | 69717688 | bgmi